Molecular changes associated with prostate cancer development

Analytical and Quantitative Cytology and Histology

Volumn 23, Issue 1, 2001, Pages 67-88

  Ruijter, E ^a   Montironi, R ^a   Van de Kaa, C ^a   Schalken, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen receptors; Oncogenes; Prostate carcinogenesis.; Prostatic neoplasms

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOLECULAR GENETICS; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ONCOGENES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TELOMERASE; VITAMIN D;

EID: 0035115916     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (234)

1. The prostate: An increasing medical problem
2. The association of oncogenic human papilloma viruses with urologic malignancy: The controversies and clinical implications
3. Oncogenes in prostate cancer
4. Tumor suppressor genes in prostate cancer
5. Molecular genetics of prostate carcinoma
6. The molecular concept of prostate carcinoma
7. The molecular biology of the prostate
8. Characterization of the cytosol androgen receptor of the human prostate
9. Antiandrogens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation
10. Mechanisms of action of steroid hormones
11. Challenges in the management of prostate carcinoma
12. Mutation of the androgen-receptor gene in metastatic, androgen-independent prostate cancer
13. Science behind total androgen blockade: From gene to combination therapy
14. The androgen receptor gene mutations database
15. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer
16. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men
17. Androgen-receptor gene structure and function in prostate cancer
18. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
19. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization
20. The antiandrogen withdrawal syndrome
21. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome
22. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
23. Androgen receptor gene mutations in prostate cancer
24. Androgen receptor gene mutations in human prostate cancer
25. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis
26. A genetic sequence change in the 3′-noncoding region of the androgen receptor gene in prostate carcinoma
27. Mutations in the androgen receptor gene are associated with progression of human prostate carcinoma to androgen independence
28. Do androgen receptor mutations have a role in androgen independent prostatic carcinoma?
29. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer
30. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
31. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
32. Regulation and mechanisms of mammalian gene amplification
33. Gene amplification and tumor progression
34. Stimulation of androgen-regulated transactivation by modulation of protein phosphorylation
35. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor
36. Regulation of prostatic growth and function by peptide growth factors
37. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups
38. The androgen receptor gene GGN microsatellite and prostate cancer risk
39. The N-terminal domain of the human androgen receptor is encoded by one, large exon
40. Trinucleotide (GNN) repeat polymorphism in the androgen receptor gene
41. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
42. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
43. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
44. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
45. Association of prostate cancer risk with genetic polymorphisms in Vitamin D receptor and androgen receptor
46. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
47. Abnormal androgen binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy)
48. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
49. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar atrophy
50. Spinal and bulbar muscular atrophy: Androgen receptor dysfunction caused by a trinucleotide repeat expansion
51. n-expanded neuropathies
52. Transcriptional activation and nuclear targeting signals of the human androgen receptor
53. Mutations in the androgen receptor
54. Reduced androgen receptor gene expression with first exon CAG repeat expansions
55. CAG-repeat expansions in androgen receptor in Kennedy's disease is not a loss of function mutation
56. 1,25(OH)2-Vitamin D3 receptors: Gene regulation and genetic circuitry
57. Stable expression of the nuclear Vitamin D receptor in the human prostatic carcinoma cell line JCA-1: Evidence that the antiproliferative effects of 1 alpha, 25 dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway
58. The vitamin D receptor: Structure and transcriptional activation
59. Is vitamin D deficiency a risk factor for prostate carcinoma?
60. Increased skin pigment reduces the capacity of skin to synthesize vitamin D3
61. Geographical patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation
62. Vitamin D and prostate cancer
63. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
64. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha, 25 dihydroxyvitamin D3 in the androgen-dependent LNCaP cells
65. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
66. The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3)
67. 1 Alpha, 25-dihydroxyvitamin D (calcitrol) inhibits the invasiveness of human prostate cancer cells
68. 1,25-Dihydroxyvitamin D and EB1089 inhibit prostate cancer metastasis in vivo
69. Antiproliferative effect of 1 alpha, 25 dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 and persistent G1 accumulation
70. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
71. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitrol)
72. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3
73. Vitamin D and prostate cancer: A prediagnostic study with stored sera
74. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
75. Apal, BsmI, EcoRV and TaqI polymorphisms at the human vitamin D receptor gene locus in Caucasians, blacks and Asians
76. Prediction of bone density from vitamin D receptor alleles
77. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies
78. Association of prostate cancer with vitamin D receptor gene polymorphism
79. Vitamin D polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
80. Cloning and expression of full-length cDNA encoding human vitamin D receptor
81. Allelic variation and the vitamin D receptor
82. Vitamin D receptor: No evidence for allele-specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism
83. A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: Utility of single-strand conformation polymorphism analysis for heterozygous carrier detection
84. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women
85. A novel polymorphism in the vitamin D receptor gene and bone mineral density: Study of vitamin D receptor expression and function in COS-7 cells
86. Hypomethylation of DNA in pathological conditions of the human prostate
87. Deletional, mutational, and methylation analysis of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
88. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
89. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
90. 5-Aza-2′-deoxycytidine: Cell differentiation and DNA methylation
91. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer
92. Cytidine methylation of regulatory sequences near the pi-class glutathione s-transferase gene accompanies human prostatic carcinogenesis
93. Hypermethylation of chromosome 17p locus D17s5 in human prostate tissue
94. Specific association of human telomerase activity with immortalized cells and cancer
95. Telomeres shorten during aging of human fibroblasts
96. Telomerase activity: A prevalent marker of malignant human prostate tissue
97. Structure and function of telomeres
98. The human telomere transferase is a ribonuclear protein that synthesizes TTAGGG repeats
99. Detection of telomerase activity in human prostate: A diagnostic marker for prostatic cancer?
100. Telomerase activity in primary prostate cancer
101. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium
102. Detection of telomerase activity in prostate cancer by needle biopsy
103. Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas
104. Genetic alterations in prostate adenocarcinoma
105. Ras gene mutations in human prostate carcinoma
106. Activated ras alleles in human carcinoma of the prostate are rare
107. Genetic changes associated with prostate cancer in humans
108. Ras, p53 and HPV status in benign and malignant prostate tumors
109. Infrequent RAS oncogene mutations in human prostate cancer
110. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas
111. Comparison of ras activation in prostate carcinoma in Japanese and American men
112. DNA binding by the Myc oncoprotein
113. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia
114. In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma
115. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers
116. Expression of the c-myc protooncogene in prostatic tissue
117. Growth factor involvement and oncogene expression in prostatic tumours
118. Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate
119. Growth factors and oncogenes in prostate cancer
120. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
121. Transfected neu oncogene induces human prostate cancer metastasis
122. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues
123. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
124. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia
125. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study
126. c-erbB-2 oncoprotein expression in primary human tumors
127. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
128. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer
129. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression
130. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate
131. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
132. Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: Comparison of cryostat and paraffin wax sections and effect of fixation
133. C-erbB-2 immunostaining: Problems with interpretation
134. HER2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
135. Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q
136. Allelotyping of human prostatic adenocarcinoma
137. Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumors
138. Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma
139. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma
140. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer
141. Identification and characterization of proximal 6q deletions in prostate cancer
142. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression
143. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate
144. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21
145. Homozygous deletions and frequent allelic loss of chromosome 8p22 in human prostate cancer
146. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma
147. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3
148. Loss of heterozygosity on chromosomes 10 and 17 in clinically locallized prostate carcinoma
149. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer
150. Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer
151. p53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer
152. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer
153. Allelic loss on chromosome 10 in prostate adenocarcinomas
154. Loss of the chromosomal region 10q23-25 in prostate cancer
155. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer
156. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis
157. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
158. Distinct regions of allelic loss on 13q in prostate cancer
159. Chromosome 16 in primary prostate cancer: A microsatellite analysis
160. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers
161. An uncertain role for p53 gene alterations in human prostate cancers
162. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer
163. Allelic loss in locally metastatic, multisampled prostate carcinoma
164. Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer
165. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle
166. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma
167. Suppression of tumorigenicity of human PCa cells by replacing a mutated RB gene
168. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas
169. Alterations of the retinoblastoma gene in human prostate adenocarcinoma
170. Retinoblastoma gene mutations in primary human PCa
171. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas
172. Molecular abnormalities in benign prostatic hypertrophy
173. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
174. The p53 tumor suppressor gene
175. p53 mutations in human cancers
176. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
177. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues
178. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
179. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma
180. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers: Investigation by temperature gradient gel electrophoresis (TGGE)
181. Identification of p53 mutations in archival prostate tumors: Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay
182. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer
183. p53 oncogene mutations in human prostate cancer specimens
184. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer
185. p53 gene alterations in human prostate carcinoma
186. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer
187. Frequency and characterization of p53 mutations in clinically localized prostate cancer
188. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy
189. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma
190. Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications
191. Mutant p53 expression in prostate carcinoma
192. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer
193. Prognostic factors in prostate cancer
194. p53 immunohistochemical and genetic alterations are associated with post-irradiated locally persistent prostate carcinoma
195. p53 mutations increase resistance to ionizing radiation
196. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines
197. p53 is required for radiation induced apoptosis in mouse thymocytes
198. Prognostic factors in prostate cancer
199. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy
200. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610
201. Cadherin cell adhesion receptors as a morphogenetic regulator
202. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion
203. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role
204. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells
205. Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict invasive behavior of L-cells
206. Microwave-stimulated fixation of entire prostatectomy specimens
207. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
208. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: Correlation with patient survival
209. Expression of E-cadherin in primary and metastatic prostate cancer
210. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate carcinoma
211. Decreased expression of E-cadherin in the progression of rat prostatic cancer
212. Downregulation of E-cadherin expression in Madin darby canine kidney (MDCK) cells inside tumors of nude mice
213. The role of E-cadherin mutations in bladder and prostate cancer: Is E-cadherin a classical tumor suppressor gene?
214. The cytoplasmic domain of the cell adhesion molecule uvomorulin associated with three independent proteins structurally related in different species
215. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells
216. Defective E-cadherin function in urological cancers: Clinical implications and molecular mechanisms
217. Assignment of the human alpha-catenin gene (CTNNA1) to chromosome 5q21-q22
218. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer
219. β-catenin mutations in human prostate cancer
220. Association of the APC gene product with beta-catenin
221. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
222. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13
223. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
224. Significance of CD44 gene products for cancer diagnosis and disease evaluation
225. Downregulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
226. Altered expression of CD44 in human prostate cancer during progression
227. Decreased levels of CD44 protein and mRNA in prostate carcinoma: Correlation with tumor grade and ploidy
228. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
229. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
230. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
231. Homozygous deletions of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas
232. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
233. Analysis of PTEN and the 10q23 region in primary prostate cancer